IVD raw materials supplier Medix Biochemica has purchased a 100% stake in the US-based biotechnology company Bioresource Technology (BRT) to expand its base matrix capabilities and strengthen its presence in the US.
With the acquisition, Medix Biochemica will provide its customers with a comprehensive offering of raw materials for their IVD quality control products.
The deal is said to align with Medix Biochemica’s plan to become the IVD industry’s first-choice raw material partner and support clients’ efforts to further streamline their supply chains.
BRT’s organisation and operations will be integrated into Medix Biochemica’s IVD Biomaterials Business Unit in St. Louis, Missouri, which also manufactures native antigens, enzymes, proteins, and biologicals.
Following the acquisition, BRT’s operations will continue in Weston, Florida, and BRT’s president Derik Reichenbach and CEO Ron Dilling will serve as strategic advisors.
Medix Biochemica CEO Steve Ferguson said: “Together, we have the potential to broaden our offering to IVD companies across the globe.
“There is an excellent complimentary offering between our portfolios, enabling Medix Biochemica to be a comprehensive partner for IVD companies requiring quality raw materials for QC products.”
Ferguson added: “With our complete offering of biological samples, processed plasma, base matrices, native enzymes, proteins, antibodies or antigens and our depth of expertise, we can dramatically reduce time to market for IVD companies whatever their need.
“Our vision is to be the first-choice partner for the IVD industry, and the team at BRT takes us one step closer.”
Founded in 1984 by Dr David Reichenbach, BRT is a producer of high-quality base matrices and other critical raw materials to many of the world’s largest IVD manufacturers.
The company manufactures its products in a state-of-the-art, ISO 13485:2016 certified, 26,000ft² facility in Weston, Florida, and employs a highly-skilled staff of approximately 20 specialists.
